PERRIGO PROMOTES ALISON IVES TO ROLE OF CHIEF SCIENTIFIC OFFICER

Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) has appointed Ms. Alison Ives as Executive Vice President and Chief Scientific Officer. Ms. Ives will oversee global research and development and regulatory efforts, joining the Company’s Operating Committee. CEO Murray S. Kessler emphasized her 20 years of experience, highlighting her role in enhancing Perrigo's product portfolio, which now has over $500 million in potential revenue. Ms. Ives expressed confidence in delivering innovation with her team at Perrigo, reinforcing the company's commitment to consumer self-care.

Positive

• Appointment of Alison Ives as Chief Scientific Officer enhances leadership in R&D.
• Perrigo's product portfolio potential is over $500 million.
• Ives brings 20 years of experience, enhancing innovation capabilities.

Negative

• None.

DUBLIN, June 1, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) today announced that Ms. Alison Ives has been promoted to Executive Vice President and Chief Scientific Officer. In this role, Ms. Ives will be responsible for providing global oversight and coordination of Perrigo's research and development, regulatory and innovation efforts. She will join the Company's Operating Committee and report to President and Chief Executive Officer, Murray S. Kessler.

Commenting on the appointment, Mr. Kessler stated, "We are building the next leaders of Perrigo through both internal and external talent. Perrigo's Scientific Office plays an incredibly important role working with our businesses to propel innovation across a wide range of regulatory categories and geographical regions. After leading our Consumer Self-Care International Regulatory Affairs and then our Consumer Self-Care Americas R&D teams, Alison worked diligently to ensure the health of Perrigo's product portfolio and helped establish a strategic framework that will fuel future innovation. Her 20 years of regulatory and R&D experience, along with her proven expertise in driving product development and portfolio management will be essential for accelerating our consumer self-care growth." 

Ms. Ives said, "I am honoured to have been promoted to this important role for Perrigo. In the past few years, under Jim Dillard's leadership, we have made enormous progress to strengthen the pipeline to more than $500 million in potential revenue. Together with the many talented people in our organization, I am confident that we will deliver highly successful and much needed innovation for customers and consumers." 

Ms. Ives, who joined Perrigo through the acquisition of Omega Pharma in 2015, previously worked for 11 years with AstraZeneca in a variety of regional and global leadership roles within the Scientific office, while sitting on New Product Development Teams across five therapeutic areas. Early in her career, she worked as a laboratory biochemist, researching drug discovery targets before making the move into industry. In 2021, Ms. Ives received a prestigious MBE award from the UK government for services to healthcare, reflecting her lifelong passion to make lives better.

About Perrigo

Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Led by its consumer self-care strategy, Perrigo is the largest store brand OTC player in the U.S. in the categories in which it competes under customer 'own brand' labels and a top 10 OTC company by revenue in Europe. Visit Perrigo online at www.perrigo.com. 

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "forecast," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the effect of the coronavirus (COVID-19) pandemic and its variants and associated supply chain impacts on the Company's business; general economic, credit, and market conditions; the impact of the war in Ukraine and any escalation thereof, including the effects of economic and political sanctions imposed by the United States, United Kingdom, European Union, and other countries related thereto; the outbreak or escalation of conflict in other regions where we do business; future impairment charges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; resolution of uncertain tax positions, including the Company's appeal of the draft and final Notices of Proposed Assessment ("NOPAs") issued by the U.S. Internal Revenue Service and the impact that an adverse result in any such proceedings would have on operating results, cash flows, and liquidity; pending and potential third-party claims and litigation, including litigation relating to the Company's restatement of previously-filed financial information and litigation relating to uncertain tax positions, including the NOPAs; potential impacts of ongoing or future government investigations and regulatory initiatives; potential costs and reputational impact of product recalls or sales halts; the impact of tax reform legislation and/or changes in  healthcare policy; the timing, amount and cost of any share repurchases; fluctuations in currency exchange rates and interest rates; the Company's ability to achieve the benefits expected from the sale of its Rx business and the risk that potential costs or liabilities incurred or retained in connection with that transaction may exceed the Company's estimates or adversely affect the Company's business or operations; the Company's ability to achieve the benefits expected from the acquisition of Héra SAS ("HRA Pharma") and the risks that the Company's synergy estimates are inaccurate or that the Company faces higher than anticipated integration or other costs in connection with the acquisition; risks associated with the integration of HRA Pharma, including the risk that growth rates are adversely affected by any delay in the integration of sales and distribution networks;; the consummation and success of other announced and unannounced acquisitions or dispositions, and the Company's ability to realize the desired benefits thereof; and the Company's ability to execute and achieve the desired benefits of announced cost-reduction efforts and strategic and other initiatives. An adverse result with respect to the Company's appeal of any material outstanding tax assessments or pending litigation, including securities or drug pricing matters, could ultimately require the use of corporate assets to pay such assessments, damages from third-party claims, and related interest and/or penalties, and any such use of corporate assets would limit the assets available for other corporate purposes. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2021, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-promotes-alison-ives-to-role-of-chief-scientific-officer-301558934.html

SOURCE Perrigo Company plc

FAQ

Who is the new Chief Scientific Officer of Perrigo?

Ms. Alison Ives has been promoted to Chief Scientific Officer of Perrigo.

What is the potential revenue of Perrigo's product portfolio?

Perrigo's product portfolio now has over $500 million in potential revenue.

When was Alison Ives appointed as Chief Scientific Officer?

Alison Ives was appointed as Chief Scientific Officer on June 1, 2022.

What role will Alison Ives have in Perrigo's management?

Alison Ives will oversee global R&D and regulatory efforts and join the Operating Committee.

What experience does Alison Ives bring to Perrigo?

Alison Ives has 20 years of experience in regulatory affairs and R&D.